{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:22Z","timestamp":1790694082899,"version":"4.1.0"},"reference-count":142,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immunotherapy is the most promising therapeutic approach against malignant pleural mesothelioma (MPM). Despite technological progress, the number of targetable antigens or specific antibodies is limited, thus hindering the full potential of recent therapeutic interventions. All possibilities of finding new targeting molecules must be exploited. The specificity of targeting is guaranteed by the use of monoclonal antibodies, while fully human antibodies are preferred, as they are functional and generate no neutralizing antibodies. The aim of this review is to appraise the latest advances in screening methods dedicated to the identification and harnessing of fully human antibodies. The scope of identifying useful molecules proceeds along two avenues, i.e., through the antigen-first or binding-first approaches. The first relies on screening human antibody libraries or plasma from immunized transgenic mice or humans to isolate binders to specific antigens. The latter takes advantage of specific binding to tumor cells of antibodies present in phage display libraries or in responders\u2019 plasma samples without prior knowledge of the antigens. Additionally, next-generation sequencing analysis of B-cell receptor repertoire pre- and post-therapy in memory B-cells from responders allows for the identification of clones expanded and matured upon treatment. Human antibodies identified can be subsequently reformatted to generate a plethora of therapeutics like antibody-drug conjugates, immunotoxins, and advanced cell-therapeutics such as chimeric antigen receptor-transduced T-cells.<\/jats:p>","DOI":"10.3390\/cancers12040915","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T03:40:19Z","timestamp":1586403619000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting"],"prefix":"10.3390","volume":"12","author":[{"given":"Fabio","family":"Nicolini","sequence":"first","affiliation":[{"name":"Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bocchini","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Angeli","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bronte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Crin\u00f2","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mazza","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2471\/BLT.13.132118","article-title":"Asbestos: Use, bans and disease burden in Europe","volume":"92","author":"Kameda","year":"2014","journal-title":"Bull. World Health Organ."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003\u20132008","volume":"19","author":"Henley","year":"2013","journal-title":"Int. J. Occup. Environ. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","first-page":"153","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Publ. Group"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","article-title":"BAP1 regulates different mechanisms of cell death","volume":"9","author":"Affar","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","article-title":"BAP1 links metabolic regulation of ferroptosis to tumour suppression","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Dey","year":"2012","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8515-8515","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","volume":"36","author":"Zauderer","year":"2018","journal-title":"JCO"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: Correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41571-019-0291-4","article-title":"Immunotherapy trials in mesothelioma - promising results, but don\u2019t stop here","volume":"16","author":"Nowak","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cedr\u00e9s, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., and Felip, E. (2015). Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121071"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13014-019-1453-3","article-title":"Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"15","author":"Gennen","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"k3529","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: Meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0489-5","article-title":"Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors","volume":"7","author":"Conroy","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","article-title":"PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?","volume":"12","author":"Lantuejoul","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Morra","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.091","article-title":"LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: A double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: Study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): With Translational Research (TR) Biopies","volume":"12","author":"Zago","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignan Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of Immune Checkpoint Inhibitors in Mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8503-8503","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma\u2014First results","volume":"36","author":"Nowak","year":"2018","journal-title":"JCO"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study","volume":"6","author":"Morra","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"ref_53","first-page":"1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2511-2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"JCO"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in Malignant Pleural Mesothelioma","volume":"10","author":"Borm","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_57","first-page":"e4102","article-title":"First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma","volume":"11","author":"Barsky","year":"2019","journal-title":"Cureus"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"ref_59","first-page":"e26536-3","article-title":"Immunogenic cell death in radiation therapy","volume":"2","author":"Galluzzi","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.it.2013.03.005","article-title":"Adaptive immunity after cell death","volume":"34","author":"Zelenay","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/ni1330","article-title":"Lymphoid organ development: From ontogeny to neogenesis","volume":"7","author":"Drayton","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/imr.12405","article-title":"Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers","volume":"271","author":"Giraldo","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_69","first-page":"407","article-title":"Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention","volume":"7","author":"Lawand","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","article-title":"Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer","volume":"71","author":"Martinet","year":"2011","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","article-title":"Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-Term Survival for Patients With Non\u2013Small-Cell Lung Cancer With Intratumoral Lymphoid Structures","volume":"26","author":"Antoine","year":"2008","journal-title":"JCO"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","article-title":"Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma","volume":"78","author":"Silina","year":"2018","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","article-title":"Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers","volume":"20","author":"Bergomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_80","first-page":"1","article-title":"Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer","volume":"7","author":"Posch","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/bjc.2015.145","article-title":"Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer","volume":"112","author":"Hiraoka","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1085147","article-title":"Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma","volume":"5","author":"Castino","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Wirsing, A.M., Ervik, I.K., Seppola, M., Uhlin-Hansen, L., Steigen, S.E., and Hadler-Olsen, E. (2018). Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma. Mod. Pathol., 1\u201313.","DOI":"10.1038\/s41379-018-0019-5"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Loi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1309\/AJCPIXUYDVZ0RZ3G","article-title":"Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: From TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1158\/2326-6066.CIR-17-0131","article-title":"Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction","volume":"5","author":"Colbeck","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling","volume":"179","author":"Coppola","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_92","first-page":"307","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Petitprez","year":"2019","journal-title":"Nat. Publ. Group"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1078-0432.CCR-16-0081","article-title":"A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases","volume":"23","author":"Montfort","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2017.00563","article-title":"A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression","volume":"8","author":"Kast","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","article-title":"CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer","volume":"18","author":"Nielsen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4049\/jimmunol.169.4.1829","article-title":"Antigen-Driven Oligoclonal Expansion of Tumor-Infiltrating B Cells in Infiltrating Ductal Carcinoma of the Breast","volume":"169","author":"Coronella","year":"2002","journal-title":"J. Immunol."},{"key":"ref_100","first-page":"e1512458","article-title":"B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies","volume":"8","author":"Thelen","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_101","first-page":"3275","article-title":"Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas","volume":"63","author":"Nzula","year":"2003","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-12-1377","article-title":"Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases","volume":"72","author":"Cipponi","year":"2012","journal-title":"Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1089\/jir.2014.0054","article-title":"Successful combined intratumoral immunotherapy of established murine mesotheliomas requires B-cell involvement","volume":"35","author":"Krishnan","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Minnema-Luiting, J., Vroman, H., Aerts, J., and Cornelissen, R. (2018). Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041041"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/icb.2010.88","article-title":"CD40-activated B cells contribute to mesothelioma tumor regression","volume":"89","author":"Jackaman","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.3390\/ijms13055420","article-title":"Antibody phage display libraries: Contributions to oncology","volume":"13","author":"Maranhao","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"MAbs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1315-1315","DOI":"10.3389\/fimmu.2018.00118","article-title":"Next-Generation Sequencing of Antibody Display Repertoires","volume":"9","author":"Rouet","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1535-7163.MCT-07-2132","article-title":"Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies","volume":"7","author":"An","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12935-014-0147-z","article-title":"The multifaceted role of CD146\/MCAM in the promotion of melanoma progression","volume":"15","author":"Lei","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"De Kruijff, I., Timmermans, A., den Bakker, M., Trapman-Jansen, A., Foekens, R., Meijer-Van Gelder, M., Oomen-de Hoop, E., Smid, M., Hollestelle, A., and van Deurzen, C. (2018). The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers, 10.","DOI":"10.3390\/cancers10050134"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Olajuyin, A.M., Olajuyin, A.K., Wang, Z., Zhao, X., and Zhang, X. (2019). CD146 T cells in lung cancer: Its function, detection, and clinical implications as a biomarker and therapeutic target. Cancer Cell Int., 1\u201313.","DOI":"10.1186\/s12935-019-0969-9"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-08-1363","article-title":"Identification of MCAM\/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma","volume":"69","author":"Bidlingmaier","year":"2009","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13402-017-0327-7","article-title":"Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples\u2014A short report","volume":"40","author":"Beije","year":"2017","journal-title":"Cell. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7978","DOI":"10.1073\/pnas.88.18.7978","article-title":"Assembly of combinatorial antibody libraries on phage surfaces: The gene III site","volume":"88","author":"Barbas","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1073\/pnas.92.14.6537","article-title":"Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: Selection of specific antibodies from single-chain Fv fusion phage libraries","volume":"92","author":"Cai","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.130.5.2461","article-title":"Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: Antigenic dissection with cytolytic T cell clones","volume":"130","author":"Wortzel","year":"1983","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00005-014-0322-x","article-title":"Human antibody production in transgenic animals","volume":"63","author":"Osborn","year":"2015","journal-title":"Arch. Immunol. Exp."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nbt.2825","article-title":"Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery","volume":"32","author":"Lee","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/nbt1337","article-title":"From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.coi.2008.06.004","article-title":"Fully human antibodies from transgenic mouse and phage display platforms","volume":"20","author":"Lonberg","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: Software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1093\/bioinformatics\/btw526","article-title":"Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V\u2019DJer","volume":"32","author":"Mose","year":"2016","journal-title":"Bioinformatics"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0647-5","article-title":"Prognostic value of B cells in cutaneous melanoma","volume":"11","author":"Selitsky","year":"2019","journal-title":"Genome Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imr.12395","article-title":"Stable long-term cultures of self-renewing B cells and their applications","volume":"270","author":"Kwakkenbos","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Gilbert, A.E., Karagiannis, P., Dodev, T., Koers, A., Lacy, K., Josephs, D.H., Takhar, P., Geh, J.L.C., Healy, C., and Harries, M. (2011). Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019330"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4161\/mabs.27044","article-title":"The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method","volume":"6","author":"Clargo","year":"2014","journal-title":"MAbs"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/1087057114564760","article-title":"A fully automated primary screening system for the discovery of therapeutic antibodies directly from B cells","volume":"20","author":"Tickle","year":"2015","journal-title":"J. Biomol. Screen"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm.1966","article-title":"A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood","volume":"15","author":"Jin","year":"2009","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/nprot.2016.093","article-title":"High-quality full-length immunoglobulin profiling with unique molecular barcoding","volume":"11","author":"Turchaninova","year":"2016","journal-title":"Nat. Protoc."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:16:41Z","timestamp":1760174201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":142,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cancers12040915"],"URL":"https:\/\/doi.org\/10.3390\/cancers12040915","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]}}}